<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>M Hoyle | Tristan Snowsill</title>
    <link>/author/m-hoyle/</link>
      <atom:link href="/author/m-hoyle/index.xml" rel="self" type="application/rss+xml" />
    <description>M Hoyle</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>Â© 2020 Tristan Snowsill</copyright><lastBuildDate>Fri, 01 Mar 2019 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/images/icon_hu050d7ab96a8b87ebb29a3f4b58eca100_52805_512x512_fill_lanczos_center_2.png</url>
      <title>M Hoyle</title>
      <link>/author/m-hoyle/</link>
    </image>
    
    <item>
      <title>Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation</title>
      <link>/publication/varley-campbell-2019-three-biomarker-tests-to-help-diagnose-preterm-labour/</link>
      <pubDate>Fri, 01 Mar 2019 00:00:00 +0000</pubDate>
      <guid>/publication/varley-campbell-2019-three-biomarker-tests-to-help-diagnose-preterm-labour/</guid>
      <description></description>
    </item>
    
    <item>
      <title>BIOMARKER TESTS TO HELP DIAGNOSE PRETERM LABOUR IN SYMPTOMATIC WOMEN WITH INTACT MEMBRANES: A SYSTEMATIC REVIEW</title>
      <link>/publication/barnish-2018-biomarker-tests-to-help-diagnose-preterm-labour/</link>
      <pubDate>Sat, 01 Sep 2018 00:00:00 +0000</pubDate>
      <guid>/publication/barnish-2018-biomarker-tests-to-help-diagnose-preterm-labour/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England</title>
      <link>/publication/tikhonova-2018-economic-analysis-of-first-line-treatment-with-cetuximab/</link>
      <pubDate>Sun, 01 Jul 2018 00:00:00 +0000</pubDate>
      <guid>/publication/tikhonova-2018-economic-analysis-of-first-line-treatment-with-cetuximab/</guid>
      <description></description>
    </item>
    
    <item>
      <title>The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: A systematic review and economic evaluation</title>
      <link>/publication/huxley-2017-the-clinical-effectiveness-and-cost-effectiveness-of-cetuximab/</link>
      <pubDate>Sun, 01 Jan 2017 00:00:00 +0000</pubDate>
      <guid>/publication/huxley-2017-the-clinical-effectiveness-and-cost-effectiveness-of-cetuximab/</guid>
      <description></description>
    </item>
    
    <item>
      <title>AZACITIDINE FOR TREATING ACUTE MYELOID LEUKAEMIA: A NICE SINGLE TECHNOLOGY APPRAISAL</title>
      <link>/publication/tikhonova-2016-azacitidine-for-treating-acute-myeloid-leukaemia/</link>
      <pubDate>Tue, 01 Nov 2016 00:00:00 +0000</pubDate>
      <guid>/publication/tikhonova-2016-azacitidine-for-treating-acute-myeloid-leukaemia/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model</title>
      <link>/publication/jones-hughes-2016-immunosuppressive-therapy-for-kidney-transplantation/</link>
      <pubDate>Mon, 01 Aug 2016 00:00:00 +0000</pubDate>
      <guid>/publication/jones-hughes-2016-immunosuppressive-therapy-for-kidney-transplantation/</guid>
      <description></description>
    </item>
    
    <item>
      <title>COST EFFECTIVENESS OF CETUXIMAB AND PANITUMUMAB FOR FIRST-LINE RAS WT METASTATIC COLORECAL CANCER</title>
      <link>/publication/tikhonova-2016-cost-effectiveness-of-cetuximab-and-panitumumab/</link>
      <pubDate>Sun, 01 May 2016 00:00:00 +0000</pubDate>
      <guid>/publication/tikhonova-2016-cost-effectiveness-of-cetuximab-and-panitumumab/</guid>
      <description></description>
    </item>
    
    <item>
      <title>The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): A systematic review and economic model</title>
      <link>/publication/crathorne-2016-the-effectiveness-and-cost-effectiveness-of-erythropoiesis/</link>
      <pubDate>Mon, 01 Feb 2016 00:00:00 +0000</pubDate>
      <guid>/publication/crathorne-2016-the-effectiveness-and-cost-effectiveness-of-erythropoiesis/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Immunosuppressive therapy for renal transplantation in adults: a systematic review and network meta-analyses.</title>
      <link>/publication/haasova-2016-immunosuppressive-therapy-for-renal-transplantation-in-adults/</link>
      <pubDate>Fri, 01 Jan 2016 00:00:00 +0000</pubDate>
      <guid>/publication/haasova-2016-immunosuppressive-therapy-for-renal-transplantation-in-adults/</guid>
      <description></description>
    </item>
    
    <item>
      <title>A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients</title>
      <link>/publication/snowsill-2015-a-model-based-assessment-of-the-cost-utility-of-strategies/</link>
      <pubDate>Wed, 01 Apr 2015 00:00:00 +0000</pubDate>
      <guid>/publication/snowsill-2015-a-model-based-assessment-of-the-cost-utility-of-strategies/</guid>
      <description></description>
    </item>
    
    <item>
      <title>MODEL-BASED COST-UTILITY ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR THE TREATMENT OF CANCER-TREATMENT INDUCED ANAEMIA IN THE UK NHS</title>
      <link>/publication/snowsill-2014-model-based-cost-utility-analysis-of-erythropoiesis-stimulating-agents/</link>
      <pubDate>Sat, 01 Nov 2014 00:00:00 +0000</pubDate>
      <guid>/publication/snowsill-2014-model-based-cost-utility-analysis-of-erythropoiesis-stimulating-agents/</guid>
      <description></description>
    </item>
    
    <item>
      <title>1498P WHAT IS THE CLINICAL EFFECTIVENESS OF ERYTHROPOIESIS STIMULATING AGENTS FOR THE TREATMENT OF CANCER TREATMENT-INDUCED ANAEMIA?</title>
      <link>/publication/crathorne-2014-what-is-the-clinical-effectiveness-of-erythropoiesis/</link>
      <pubDate>Mon, 01 Sep 2014 00:00:00 +0000</pubDate>
      <guid>/publication/crathorne-2014-what-is-the-clinical-effectiveness-of-erythropoiesis/</guid>
      <description></description>
    </item>
    
    <item>
      <title>A COST-EFFECTIVENESS ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR TREATING CANCER-TREATMENT INDUCED ANAEMIA</title>
      <link>/publication/huxley-2014-a-cost-effectiveness-analysis-of-erythropoiesis-stimulating/</link>
      <pubDate>Mon, 01 Sep 2014 00:00:00 +0000</pubDate>
      <guid>/publication/huxley-2014-a-cost-effectiveness-analysis-of-erythropoiesis-stimulating/</guid>
      <description></description>
    </item>
    
    <item>
      <title>A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome</title>
      <link>/publication/snowsill-2014-a-systematic-review-and-economic-evaluation-of-diagnostic-strategies/</link>
      <pubDate>Wed, 01 Jan 2014 00:00:00 +0000</pubDate>
      <guid>/publication/snowsill-2014-a-systematic-review-and-economic-evaluation-of-diagnostic-strategies/</guid>
      <description></description>
    </item>
    
    <item>
      <title>COST-EFFECTIVENESS OF SYSTEMATIC TESTING FOR LYNCH SYNDROME IN PATIENTS NEWLY DIAGNOSED WITH COLORECTAL CANCER IN THE UNITED KINGDOM</title>
      <link>/publication/huxley-2013-cost-effectiveness-of-systematic-testing-for-lynch-syndrome/</link>
      <pubDate>Fri, 01 Nov 2013 00:00:00 +0000</pubDate>
      <guid>/publication/huxley-2013-cost-effectiveness-of-systematic-testing-for-lynch-syndrome/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
